UNSPSC 51142416: Iprazochrome

This classification denotes a serotonin antagonist with the molecular formula C12H16N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 903A9K181P, chemically known as 5,6-indolinedione, 3-hydroxy-1-isopropyl-, 5-semicarbazone (8ci) but generally known as iprazochrome, which bears US NIH Compound Identifier 6381821. European Medicines Agency schedules Iprazochrome in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08277MIG.

UNSPSC 51142416 Iprazochrome is a Commodity code that captures pharmaceutical and over-the-counter product procurement by state and local health systems, though recent solicitations under this code show minimal activity specifically tied to iprazochrome itself. The few opportunities posted reveal state and local governments buying naloxone systems, generic multi-source pharmaceuticals, and OTC products through competitive bidding and cooperative purchasing vehicles. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local facilities across multiple states including Oregon). The work spans direct product procurement through authorized wholesalers, fulfillment via quarterly or standing-order delivery schedules, and market-intelligence gathering to inform future pharmacy benefit program design.

Recent activity concentrates in the Southeast and Midwest. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023 in the source, indicating a data inconsistency) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with shipping and delivery costs included in bidder proposals. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co.—with products effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission posted a Request for Information on April 3, 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities, signaling potential future formal solicitations but no current binding opportunity. The code shows limited recent procurements specifically matching iprazochrome nomenclature; the opportunities tagged under this code primarily reflect broader pharmaceutical and OTC supply contracting.